Topiramate (All indications)

Emotional disorders

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15240
R62660		 Dreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023 Anxiety disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective exposed to other treatment, sick excluded Adjustment: No 1.52 [0.73;3.15] C
excluded (control group) 		8/290   97/5,288 105 290
ref
S15233
R62577		 Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Anxiety disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective unexposed, sick Adjustment: Yes 1.32 [0.65;2.72] 8/290   458/22,203 466 290
ref
S8582
R28557		 Bromley (Topiramate), 2016 Maladaptive behavior: Anxiety (BASC) (5-9 years old) during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, sick Adjustment: No extrapolated (cont. endpoint) 0.61 [0.27;1.42] -/27   -/55 - 27
ref
Total 2 studies 0.92 [0.43;1.97] 466 317
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023Dreier, 2023 1 1.32[0.65; 2.72]46629054%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Bromley (Topiramate), 2016Bromley, 2016 2 0.61[0.27; 1.42]-2746%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 48% 0.92[0.43; 1.97]4663170.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Epilepsy) (Controls unexposed, sick; 2: Topiramate;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.92[0.43; 1.97]46631748%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.92[0.43; 1.97]46631748%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 2 Tags Adjustment   - No  - No 0.61[0.27; 1.40]-27 -NABromley (Topiramate), 2016 1   - Yes  - Yes 1.32[0.65; 2.70]466290 -NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 1 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 0.61[0.27; 1.40]-27 -NABromley (Topiramate), 2016 1 All studiesAll studies 0.92[0.43; 1.97]46631748%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 15240

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.92[0.43; 1.97]46631748%NADreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 Bromley (Topiramate), 2016 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.52[0.73; 3.15]105290 -NADreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023 10.510.01.0